AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
Jan 7 (Reuters) - AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Shares of Revolution were up 10% in afternoon trading.
(Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vistra’s Meta PPA Fuels AI Energy Leadership—Yet Uncertainty Persists
Egypt: Standard Chartered notes inflation recovery slows easing
Levi's AI Play: Closing the $3.5B DTC Gap with Store Flow Metrics
3 Reasons to Consider Selling ASUR and One Alternative Stock Worth Buying
Trending news
MoreCrypto prices
More
